Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: An open-label, two-centre, randomised controlled trial

The Lancet Infectious Diseases

Volumn 16, Issue 5, 2016, Pages 535-545

  Arjyal, Amit ^a   Basnyat, Buddha ^a,b,d   Nhan, Ho Thi ^a   Koirala, Samir ^a   Giri, Abhishek ^a   Joshi, Niva ^a   Shakya, Mila ^a   Pathak, Kamal Raj ^a   Mahat, Saruna Pathak ^a   Prajapati, Shanti Pradhan ^a   Adhikari, Nabin ^a   Thapa, Rajkumar ^c   Merson, Laura ^a,d   Gajurel, Damodar ^f   Lamsal, Kamal ^f   Lamsal, Dinesh ^f   Yadav, Bharat Kumar ^c   Shah, Ganesh ^c   Shrestha, Poojan ^a   Dongol, Sabina ^a   Karkey, Abhilasha ^a   Thompson, Corinne N ^a,d   Thieu, Nga Tran Vu ^d   Thanh, Duy Pham ^d   Baker, Stephen ^a,d,g   Thwaites, Guy E ^a,d   Wolbers, Marcel ^a,d   Dolecek, Christiane ^a,d,e   more..

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b Global Antibiotic Resistance Partnership   (Nepal)

^c PATAN HOSPITAL   (Nepal)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f CIVIL SERVICE HOSPITAL   (Nepal)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; GATIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BLOOD CULTURE; CHILD; CONTROLLED STUDY; COUGHING; DISEASE CLEARANCE; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSGLYCEMIA; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIC50; MIC90; MULTICENTER STUDY; NEPAL; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SALMONELLA ENTERICA SEROVAR PARATYPHI A; SALMONELLA ENTERICA SEROVAR PARATYPHI B; SALMONELLA ENTERICA SEROVAR PARATYPHI C; SALMONELLA ENTERICA SEROVAR TYPHI; SIDE EFFECT; TREATMENT OUTCOME; TYPHOID FEVER; VOMITING; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; ISOLATION AND PURIFICATION; SALMONELLA ENTERICA; TREATMENT FAILURE; YOUNG ADULT;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; NEPAL; SALMONELLA ENTERICA; SALMONELLA TYPHI; TREATMENT FAILURE; TYPHOID FEVER; YOUNG ADULT;

EID: 84955242501     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00530-7     Document Type: Article

References (31)

1. Buckle GC, Walker CLF, Black RE Typhoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010. J Glob Health 2012, 2:10401.
2. Crump JA, Luby SP, Mintz ED The global burden of typhoid fever. Bull World Health Organ 2004, 82:346-353.
3. Maskey AP, Basnyat B, Thwaites GE, Campbell JI, Farrar JJ, Zimmerman MD Emerging trends in enteric fever in Nepal: 9124 cases confirmed by blood culture 1993-2003. Trans R Soc Trop Med Hyg 2008, 102:91-95.
4. Karkey A, Aryjal A, Basnyat B, Baker S Kathmandu, Nepal: still an enteric fever capital of the world. J Infect Dev Ctries 2008, 2:461-465.
5. Background document: the diagnosis, treatment and prevention of typhoid fever 2003, 19-23. WHO, World Health Organization, Geneva.
6. Parry CM, Vinh H, Chinh NT, et al. The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapy. PLoS Negl Trop Dis 2011, 5:e1163.
7. Parry CM, Thuy CT, Dongol S, et al. Suitable disk antimicrobial susceptibility breakpoints defining Salmonella enterica serovar Typhi isolates with reduced susceptibility to fluoroquinolones. Antimicrob Agents Chemother 2010, 54:5201-5208.
8. Dave J, Sefton A Enteric fever and its impact on returning travellers. Int Health 2015, 7:163-168.
9. Johnston V, Stockley JM, Dockrell D, et al. Fever in returned travellers presenting in the United Kingdom: recommendations for investigation and initial management. J Infect 2009, 59:1-18.
10. Wallace MR, Yousif AA, Mahroos GA, et al. Ciprofloxacin versus ceftriaxone in the treatment of multiresistant typhoid fever. Eur J Clin Microbiol Infect Dis 1993, 12:907-910.
11. Smith MD, Duong NM, Hoa NT, et al. Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. Antimicrob Agents Chemother 1994, 38:1716-1720.
12. Tran TH, Nguyen MD, Huynh DH, et al. A randomized comparative study of fleroxacin and ceftriaxone in enteric fever. Trans R Soc Trop Med Hyg; 88: 464-65.
13. Effa EE, Lassi ZS, Critchley JA, et al. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev 2011, 11. CD004530.
14. Pandit A, Arjyal A, Day JN, et al. An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever. PLoS One 2007, 2:e542.
15. Dolecek C, Tran TP, Nguyen NR, et al. A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam. PLoS One 2008, 3:e2188.
16. Koirala S, Basnyat B, Arjyal A, et al. Gatifloxacin versus ofloxacin for the treatment of uncomplicated enteric fever in Nepal: an open-label, randomized, controlled trial. PLoS Negl Trop Dis 2013, 7:e2523.
17. Arjyal A, Basnyat B, Koirala S, et al. Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial. Lancet Infect Dis 2011, 11:445-454.
18. Bhutta ZA, Khan IA, Shadmani M Failure of short-course ceftriaxone chemotherapy for multidrug-resistant typhoid fever in children: a randomized controlled trial in Pakistan. Antimicrob Agents Chemother 2000, 44:450-452.
19. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ Typhoid fever. N Engl J Med 2002, 347:1770-1782.
20. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement 2012, Clinical Laboratory Standards Institute, Clinical Laboratory Standards Institute, Wayne.
21. Kalbfleisch JD, Prentice RL The statistical analysis of failure time data 2002, John Wiley & Sons, Hoboken. 2nd edn.
22. Team R R: A language and environment for statistical computing 2012, R Foundation for Statistical Computing, Vienna, (accessed Nov 1, 2015). https://cran.r-project.org.
23. Haybittle JL Repeated assessment of results in clinical trials of cancer treatments. Br J Radiol 1971, 44:793-797.
24. Crump JA, Sjölund-Karlsson M, Gordon MA, Parry CM Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive salmonella infections. Clin Microbiol Rev 2015, 28:901-937.
25. Wong VK, Baker S, Pickard DJ, et al. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events. Nat Genet 2015, 47:632-639.
26. Baker S, Duy PT, Nga TVT, et al. Fitness benefits in fluoroquinolone-resistant Salmonella Typhi in the absence of antimicrobial pressure. Elife 2013, 2:e01229.
27. Zimmerman MD, Murdoch DR, Rozmajzl PJ, et al. Murine typhus and febrile illness, Nepal. Emerg Infect Dis 2008, 14:1656-1659.
28. Thompson CN, Blacksell SD, Paris DH, et al. Undifferentiated febrile illness in Kathmandu, Nepal. Am J Trop Med Hyg 2015, 92:875-878.
29. Parry CM, Wijedoru L, Arjyal A, Baker S The utility of diagnostic tests for enteric fever in endemic locations. Expert Rev Anti Infect Ther 2011, 9:711-725.
30. Parry CM, Thieu NTV, Dolecek C, et al. Clinically and microbiologically derived azithromycin susceptibility breakpoints for Salmonella enterica serovar S Typhi and Paratyphi A. Antimicrob Agents Chemother 2015, 59:2756-2764.
31. Kobayashi T, Hayakawa K, Mawatari M, et al. Case report: failure under azithromycin treatment in a case of bacteremia due to Salmonella enterica Paratyphi A. BMC Infect Dis 2014, 14:404.